Diabetes exacerbates inflammatory bowel disease in mice with diet-induced obesity

Figure 4 Body weight, blood glucose, clinical disease activity, histopathologic disease activity, and intestinal barrier integrity in diabetic chow-fed mice. A: Body weight; B: Blood glucose in chow-fed non-obese mice that received either vehicle (Veh) or streptozotocin (STZ) to induce diabetes and were then given dextran sodium sulfate (DSS) to induce colitis; C: Clinical DSS colitis disease activity scores in normoglycemic and hyperglycemic mice; D: Colon length; E: Spleen weight-to-body weight ratios; F: Colonic Alcian blue staining; G: Tight junction protein E-cadherin staining quantified from areas with intact colonic epithelium. n = 4-7 per group, mean ± standard error of the mean. ^aP < 0.05, and comparison noted in (C) is between chow/Veh/DSS and chow/STZ/DSS groups for days 3-7 of DSS. DSS: Dextran sodium sulfate; Veh: Vehicle; STZ: Streptozotocin.